Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy.
Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.
Annaberdyev
Shohrat
S
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Shohrat@case.edu
Gibbons
Joseph
J
Hardacre
Jeffrey M
JM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit